Literature DB >> 21553103

Prognostic significance of galectin-3 and cyclin D1 expression in undifferentiated nasopharyngeal carcinoma.

Mustafa Fuat Acikalin1, Durmus Etiz, Melek Kezban Gurbuz, Erkan Ozudogru, Funda Canaz, Ertugrul Colak.   

Abstract

Galectin-3 was shown to be involved in various biological events, including cell growth, adhesion, differentiation, angiogenesis, apoptosis, tumorigenesis, and metastasis. The prognostic significance of galectin-3 expression has already been evaluated in several cancers. However, its prognostic role has not been investigated in nasopharyngeal carcinoma. The loss of cell cycle control is one of the critical steps in the development of nasopharyngeal carcinoma. Cyclin D1 is one of the key proteins involved in cell cycle control and is essential for G1/S phase transition. Overexpression of cyclin D1 has been observed in several human cancers. In the present study, the expression of galectin-3 and cyclin D1 was evaluated with immunohistochemical analysis in 45 patients diagnosed as undifferentiated nasopharyngeal carcinoma and expression of these proteins was correlated with clinicopathological parameters and prognosis. Multivariate analysis showed that older age (>50 vs. ≤50) (P = 0.028), distant metastasis at presentation (M(1) vs. M(0)) (P = 0.001), and increased galectin-3 expression (>5% vs. ≤5%) (P = 0.025) were independently correlated with poor overall survival. We found no statistically significant correlation between cyclin D1 immunoexpression and disease outcome. The Spearman's correlation coefficient revealed a significant correlation between galectin-3 and cyclin D1 expression (r = 0.425; P = 0.004). Our findings suggested that the immunohistochemical analysis of galectin-3 might be useful in predicting prognosis in nasopharyngeal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21553103     DOI: 10.1007/s12032-011-9971-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  36 in total

Review 1.  Galectin-3 as a multifunctional protein.

Authors:  Anna Krześlak; Anna Lipińska
Journal:  Cell Mol Biol Lett       Date:  2004       Impact factor: 5.787

2.  Decreased expression of galectin-3 is associated with progression of human breast cancer.

Authors:  V Castronovo; F A Van Den Brûle; P Jackers; N Clausse; F T Liu; C Gillet; M E Sobel
Journal:  J Pathol       Date:  1996-05       Impact factor: 7.996

3.  Clinical significance of Galectin-3 in clear cell renal cell carcinoma.

Authors:  Manabu Sakaki; Tomoharu Fukumori; Tomoya Fukawa; Essam Elsamman; Avirmed Shiirevnyamba; Hiroyoshi Nakatsuji; Hiro-omi Kanayama
Journal:  J Med Invest       Date:  2010-02

4.  Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma.

Authors:  Y Honjo; H Inohara; S Akahani; T Yoshii; Y Takenaka; J Yoshida; K Hattori; Y Tomiyama; A Raz; T Kubo
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

5.  Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck.

Authors:  R Michalides; N van Veelen; A Hart; B Loftus; E Wientjens; A Balm
Journal:  Cancer Res       Date:  1995-03-01       Impact factor: 12.701

6.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

7.  Galectin-3, a novel binding partner of beta-catenin.

Authors:  Tatsuo Shimura; Yukinori Takenaka; Souichi Tsutsumi; Victor Hogan; Akira Kikuchi; Avraham Raz
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

8.  Differential expression of galectin-3, beta-catenin, and cyclin D1 in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma of salivary glands.

Authors:  K L Ferrazzo; M M Neto; E dos Santos; D dos Santos Pinto; S O M de Sousa
Journal:  J Oral Pathol Med       Date:  2009-07-31       Impact factor: 4.253

9.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.

Authors:  X C Xu; A K el-Naggar; R Lotan
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

10.  Cyclin D1 and p16 expression in recurrent nasopharyngeal carcinoma.

Authors:  Ho-Sheng Lin; Gerald J Berry; Zijie Sun; Willard E Fee
Journal:  World J Surg Oncol       Date:  2006-09-05       Impact factor: 2.754

View more
  6 in total

Review 1.  The prognostic value of cyclin D1 expression in head and neck squamous cell carcinoma.

Authors:  Federico M Gioacchini; Matteo Alicandri-Ciufelli; Shaniko Kaleci; Giuseppe Magliulo; Livio Presutti; Massimo Re
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-12-12       Impact factor: 2.503

2.  Long noncoding RNA-LET, which is repressed by EZH2, inhibits cell proliferation and induces apoptosis of nasopharyngeal carcinoma cell.

Authors:  Qiuzhen Sun; Hongbing Liu; Lihua Li; Shaorong Zhang; Ke Liu; Yuehui Liu; Chunping Yang
Journal:  Med Oncol       Date:  2015-08-05       Impact factor: 3.064

3.  Galectin-3 and cyclin D1 expression in non-small cell lung cancer.

Authors:  Monika Kosacka; Paweł Piesiak; Aneta Kowal; Marcin Gołecki; Renata Jankowska
Journal:  J Exp Clin Cancer Res       Date:  2011-10-24

4.  Intranuclear accumulation of galectin-3 is an independent prognostic factor for patients with distal cholangiocarcinoma.

Authors:  Tatsuo Shimura; Yasuhide Kofunato; Ryo Okada; Rei Yashima; Yoshihisa Koyama; Kenichiro Araki; Hiroyuki Kuwano; Seiichi Takenoshita
Journal:  Oncol Lett       Date:  2017-05-25       Impact factor: 2.967

Review 5.  Prognostic Value of Molecular Markers and Implication for Molecular Targeted Therapies in Nasopharyngeal Carcinoma: An Update in an Era of New Targeted Molecules Development.

Authors:  Mu-Tai Liu; Mu-Kuan Chen; Chia-Chun Huang; Chao-Yuan Huang
Journal:  World J Oncol       Date:  2015-02-14

6.  Lectin affinity chromatography and quantitative proteomic analysis reveal that galectin-3 is associated with metastasis in nasopharyngeal carcinoma.

Authors:  Sathid Aimjongjun; Onrapak Reamtong; Tavan Janvilisri
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.